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Losartan decreases plasma levels of TGF-b1 in transplant pa- The principal cause of late graft loss after the first year
tients with chronic allograft nephropathy. of renal transplantation is a poorly understood clinico-
Background. Chronic allograft nephropathy represents the pathological entity called “chronic rejection,” and moreprincipal cause of graft loss after the first year of transplanta-
correctly referred to as “chronic allograft nephropathy,”tion. Transforming growth factor-b1 (TGF-b1) is a key factor
as the exact nature of this process is unclear. Renalin fibrogenesis and has been involved in the pathogenesis of
chronic allograft nephropathy and other chronic nephropa- transplantation with chronic allograft nephropathy ex-
thies. Experimental studies have demonstrated that the angio- hibits a gradual and progressive deterioration in renal
tensin II receptor antagonist (losartan) could decrease the syn- function in association with proteinuria and arterial hy-thesis of TGF-b1. The aim of this study was to determine the
pertension. Histology is characterized by arterial intimalplasma levels of TGF-b1 in transplant patients with chronic
and medial fibrosis and arteriolar insudative lesions, glo-allograft nephropathy, and to evaluate the effect of losartan
on TGF-b1 plasma levels and other vasoactive peptides (angio- merulosclerosis, and interstitial fibrosis with tubular at-
tensin II, plasma renin activity, aldosterone, endothelin-1, and rophy [1]. Although chronic rejection has traditionally
nitrites and nitrates). Angiotensin-converting enzyme genotypes been seen as repeated low-grade immune responses di-were also determined in all patients.
rected against allogeneic tissue, recent evidence indicatesMethods. Fourteen transplant patients with chronic allograft
that nonimmunological factors may greatly contributenephropathy were included. Treatment with losartan (50 mg)
was introduced. Consecutive determinations of TGF-b1 and to its pathogenesis, especially arterial hypertension, lipid
other vasoactive peptides were performed during follow-up. abnormalities, cyclosporine nephrotoxicity, and advanc-
Results. Patients with chronic allograft nephropathy pre- ing age in the graft donor [2]. Independent of any trig-sented higher plasma levels of TGF-b1 than the control groups.
gering events, the cause of tissue destruction in chronicThe treatment with losartan significantly decreased the plasma
allograft nephropathy is fibrogenesis or accumulation oflevels of TGF-b1 (P , 0.05) and endothelin (P , 0.05) in all
patients. The decrease of TGF-b1 was statistically correlated extracellular matrix (glomerular, arteriolar, and intersti-
with the blockade of the angiotensin II receptor (P , 0.05). tial), as is also the case in other chronic diseases of the
No significant correlation could be demonstrated between angio- kidneys and other organs. Excessive extracellular matrixtensin-converting enzyme genotypes and TGF-b, endothelin-1,
accumulation ultimately leads to loss of allograft renaland nitrite-nitrate serum levels.
function via a glomerular hyperfiltration syndrome [3].Conclusions. This study demonstrates that losartan signifi-
cantly decreases the plasma levels of TGF-b1, the most impor- Transforming growth factor-b1 (TGF-b1) is a key fi-
tant fibrogenetic factor. These results could play a decisive role brogenetic cytokine involved in the fibrosis of a number
in the treatment and prevention of chronic nephropathies, not of chronic diseases of the kidney and other organs [4].only graft nephropathy, because the intrinsic pathogenetic mech-
TGF-b1 directly stimulates the synthesis of individualanism is very similar in all forms, with a crucial roles for the
extracellular matrix components and blocks matrix degra-renal renin-angiotensin system and TGF-b1.
dation by stimulating protease inhibitors such as plasmino-
gen activator inhibitor-1 (PAI-1) [5, 6]. Recent evidence
has shown that TGF-b1 is involved in the pathogenesis
of chronic renal allograft dysfunction [7, 8], and Su-Key words: fibrogenesis, chronic nephropathy, endothelin, proteinuria,
renal allograft. thanthiran et al suggested the relationship between se-
rum levels of TGF-b1 and the predisposition to renalReceived for publication September 17, 1998
disease among the black population [9]. The productionand in revised form January 21, 1999
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angiotensin II (Ang II) induces TGF-b1 production and low-up, basal time before the introduction of losartan,
and then two, four, and eight weeks on losartan therapy.secretion by the mesangial cells, and by a direct effect
of cyclosporine A, which stimulates the synthesis and Prior to the basal point, a washout of two weeks was
required in all patients, and all antihypertensive medica-expression of TGF-b1 in vitro and in a number of cell
culture systems [10, 11]. Moreover, there is strong evi- tion was withdrawn, including calcium channel blockers,
diuretics, and b-blockers. Losartan was administereddence to suggest that the intrarenal RAS is activated in
this model of chronic cyclosporine nephropathy [12]. On once a day during the entire study, 25 mg during the
first week and 50 mg for the rest of the study. The immu-the other hand, recent studies have demonstrated that
TGF-b1 increases the production of endothelin-1 (ET-1), nosuppressive therapy was not modified during the study
period. All patients provided written informed consentwhich is considered to be the most potent vasoconstrictor
known to date, with a crucial role in the control of vascu- to participate, and the protocol was approved by the
ethical committee of our hospital.lar tone and a potential involvement in the development
of chronic renal failure [13, 14], and TGF-b1 inhibits nitric At every point in the study, the following determi-
nations were checked: arterial blood pressure, serumoxide production from endothelial cells [15]. Angioten-
sin-converting enzyme (ACE) inhibitors and the recently creatinine, creatinine clearance, serum sodium, potas-
sium, proteinuria, plasma renin activity (PRA), plasmaintroduced Ang II receptor antagonist, losartan, antago-
nize TGF-b1 expression [7]. Thus, these agents may have concentration of Ang II, aldosterone (ALDO), endo-
thelin-1 (ET-1), serum levels of nitrites and nitrates, seruma beneficial impact on chronic renal allograft dysfunc-
tion, independent of the lowering effect on the blood TGF-b1, and cyclosporine blood levels. Furthermore,
ACE genotypes were determined after DNA extractionpressure, which is an additional indication for their long-
term use in transplanted patients. at the first blood extraction. Clinical tolerance of losartan
was also recorded. Venous blood was taken for hormonalThe aims of this study were to determine the plasma
levels of TGF-b1 in transplant patients with chronic allo- determinations after 45 minutes of supine rest.
graft nephropathy and to evaluate the effect of losartan
Measurement methodson plasma levels of TGF-b1 and other vasoactive pep-
tides in these patients. Mean arterial pressure (MAP). Blood pressure was
monitored once a week during the first month and every
two weeks during the rest of the study. Blood pressure
METHODS
determinations were performed according to World
Patients Health Organization’s recommendations. An automatic
oscillometer (OMRON) was used, performing three con-Fourteen renal transplant patients (eight males) with
clinically and histologically (CADI) proven chronic allo- secutive measurements at intervals of two minutes, with
the patient in a supine position. The mean of the threegraft nephropathy were included in this study [16, 17].
All patients were hypertensive when included in the determinations was used as the reference value.
Plasma renin activity, plasma concentration of angio-study, and five of them had a clinically significant protein-
uria (.1 g/day; range, 1.6 to 4.5 g/day). The mean age tensin II, and aldosterone. Blood samples were collected
on ice in sodium ethylenediaminetetraacetic acidof the patients was 52.6 (range, 31 to 70 years), and the
mean time after renal transplantation was 53 months (18 (EDTA) tubes centrifuged at 48C; plasma samples were
frozen at 2308C until the assay was performed. PRA wasto 168 months). The etiology of primary renal disease
in five cases was chronic interstitial nephropathy, and in estimated by radioimmunoassay (Clinical Assay; Baxter,
Cambridge, MA, USA) of angiotensin I generated aftertwo cases, it was Alport syndrome; the etiology of two
cases was adult polycystic kidney disease, and it was three hours of incubation at pH 7.4 and at 378C under
conditions inhibiting further conversion of angiotensin I.chronic glomerulonephritis in three cases. In one case,
the etiology was unknown. Immunosuppressive therapy ALDO was measured using a commercial kit (Coat-A-
Count Aldosterone; Diagnostic and Products Corpora-was cyclosporine A plus prednisone in all patients.
Two control groups were evaluated for TGF-b1 plasma tion, Los Angeles, CA, USA). Ang II was determined
by radioimmunoassay (Nichols Institute, Wichjen, Thelevels: 1 of 15 transplanted patients (mean age 43 6 8
years) with normal renal function treated with cyclospo- Netherlands).
Plasma levels of endothelin-1. The ET concentrationrine and prednisone and with the same period of trans-
plantation as the study group, and another 10 healthy was measured by radioimmunoassay (Nichols Institute
Diagnostics) after extraction on Sep-Pak C18 cartridgessubjects from the laboratory (mean age 37 6 5 years).
(Water Associates, Milford, MA, USA). Plasma samples
Study design (1 ml) were acidified with 4% acetic acid (4.5 ml) and
applied to cartridges preactivated with methanol, dis-The study was an open, controlled, pilot study. The
design included four consecutive points during the fol- tilled water, and 4% acetic acid. The cartridges were
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then washed with distilled water and 25% ethanol, and Given that the aim of the study was to analyze the
patient response profile, the dependency on the sameimmunoreactive ET (irET) was eluted twice with 1 ml
4% acetic acid in 86% ethanol. The eluted ET was then patient over a period of time cannot be ignored [21].
Individual response curves were plotted to seek a generalconcentrated to dryness (Speed Vac Concentrator; Sa-
vant Instruments Inc., Farmingdale, NY, USA) and re- pattern and variability between individuals. A response
features profile analysis was based on the study of theconstituted for radioimmunoassay. The recovery rate for
the extraction procedure was 85%, as determined by the rate at which the variable changed. For each individual,
a slope estimate was obtained by applying linear regres-addition of labeled ET-1 (3500 cpm) to plasma. Cross-
reactivity of the antiserum for ET-1, -2, -3, and big ET sion to each curve. A 95% confidence interval for the
mean slope was calculated for each variable.was 100, 52, 96, and 7%, respectively. Intra-assay and
interassay coefficients of variation were 6.9 and 12.1%, A correlation bivariable analysis between TGF-b1
baseline-eight weeks and the rest of the variables (Ang II,respectively.
Nitrites and nitrates. Nitrite and nitrate (NOx) serum ET-1, and NOx at different times) was also performed.
Excel 7.0 and SPSS for Windows 95 were used toconcentrations were determined in serum by the fluo-
rometric method of Misko et al [18]. The fluorescent perform the statistical analysis.
signal was measured (Perkin Elmer, Foster City, CA,
USA) at excitation and emission wavelengths of 365 and
RESULTS
425 nm, respectively.
Table 1 summarizes the follow-up of the various pa-Transforming growth factor-b1 plasma levels. Peri-
rameters during the treatment with losartan. Arterialpheral venous blood was obtained from the patients with
blood pressure decreased significantly during the follow-EDTA as an anticoagulant and was centrifuged to 1000 g
up, from an initial mean blood pressure of 110.3 6 12for 30 minutes. The plasma was isolated and stored at
mm Hg to 95.6 6 6 mm Hg at the end of the study (P ,2708C until the assay was performed.
0.05). Renal function remained stable in all patients,To activate latent TGF-b1 into immunoreactive TGF-b1
without any significant changes. In the five patients withdetectable by the immunoassay test, we performed an
clinically relevant proteinuria, a statistically significantacidification (to 0.1 ml sample add 0.1 ml 2.5 N acetic
decline was observed from 3.5 6 0.6 to 1.9 6 0.4 g/24 hracid/10 m urea) and neutralization (adding 0.1 ml 2.7 N
(P , 0.05). Cyclosporine blood levels did not changeNaOH/1 m HEPES) procedure (pH 7.2 to 7.6). We per-
during the study period (94 6 15.5 ng/ml at the baselineformed three sample dilutions (1:12, 1:24, and 1:48) with
and 91 6 17.3 at eight weeks, P 5 NS). Clinical toleranceCalibrator Diluent RD6M. TGF-b1 was determined using
was excellent in all cases, and no patients were withdrawna solid-phase TGF-b1–specific sandwich enzyme-linked
during the study period.immunosorbent assay (ELISA; Quantykine; R&D Sys-
The Ang II serum levels increased significantly duringtems, Minneapolis, MN, USA). A TGF-b1 standard
the treatment with losartan (Fig. 1). This rise was mark-curve was constructed using 2000, 1000, 500, 250, 62.5,
edly significant at two weeks (P , 0.001), and later on,and 31.25 pg/ml of recombinant human TGF-b1 protein.
Ang II levels remained high but without statisticalThe minimum detectable level of TGF-b1 with the test
changes. ET-1 values decreased significantly from thewas 7 pg/ml.
baseline (16.0 pg/ml) to two-weeks control (10.6 pg/ml,Detection of angiotensin-converting enzyme genotype.
P , 0.05).DNA was extracted from peripheral blood leukocytes, as
Transforming growth factor-b1 serum levels decreaseddescribed earlier in the article [19]. The ACE insertion/
progressively in all patients during the treatment withdeletion (I/D) genotype was determined by polymerase
losartan (Fig. 1). The change was statistically significantchain reaction using the method and primers described
from the baseline to the controls at four and eight weeksby Ferna´ndez-Llamas et al [20].
(P , 0.05). The reduction in TGF-b1 from the baseline
Statistical analysis to eight weeks of treatment was 54.6% (13.36 to 6.10
ng/ml). At the end of the losartan therapy, TGF-b1 se-Values of the variables at baseline were analyzed to
rum levels were not statistically different from the con-check for normal distribution using normal plots and
trol group of transplanted patients (6.10 6 3.4 vs. 5.38 6Shapiro–Wilks test. After rejecting the hypothesis of nor-
2.84 ng/ml, P 5 0.5), although they were still higher thanmality, TGF-b1, Ang II, and NOx were normalized using
of the healthy group (2.33 6 0.8 ng/ml, P , 0.005).a logarithm (log) transformation. Absolute or trans-
In a profile study of serial measurements utilizing Na-formed values at baseline were compared with those at
pierian logarithms (ln), lnTGF-b1, lnAng II, ET-1, andtwo, four, and eight weeks by using the paired Student’s
lnNOx variables showed a linear trend. A mean slopet-test. To compare the TGF-b1 serum levels between the
was calculated for each variable by means of the individ-study group and the two control groups, an unpaired
Student’s t-test was applied. ual slope value. The lnTGF-b1 line slope was 20.012
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Table 1. Primary results during the study period
DBaseline-
8 Weeks Control
Baselinea 2 Weeks 4 Weeks 8 Weeks P group
MAP mm Hg 110612 105 65 102 614 95 67 0.04 10768
CCr ml/min 58630 56 628 53 628 48 620 0.63 85623
SCr lg /dl 1.9560.7 2.02 60.8 2.04 60.8 2.1 60.8 0.70 1.160.13
bCsA ng /ml 94615.5 94 620 96 630 91 617.3 0.8 93618.6
Prot b g /day 3.560.6 2.6 60.4 2.4 60.5 1.9 60.4 0.04 0.06660.08
PRA ng /ml /hr 0.9162 2.75 62.4 2.90 62.8 3.00 62.4 0.04 0.3560.24
Ang II pg /ml 26623 81 670 89 672 102690 0.001a 2068.6
ET-1 pg /ml 1666 10.667 11 65 11 64 0.03a 6.161.1
NOx nm /ml 70631 63 624 85 638 87 629 0.08 —
TGF-b1 ng /ml 13.36612 12.13 610 6.67 64 6.10 63.4 0.04 5.3862.84
Results are expressed as mean 6 sd.
Abbreviations are: MAP, mean arterial pressure; CCr, creatinine clearance; SCr, serum creatinine; bCsA, cyclosporine blood levels; Prot, proteinuria; PRA, plasma
renin activity; Ang II, angiotensin II; ET-1, endothelin-1; NOx, nitrites and nitrates; TGF-b1, transforming growth factor beta-1.
a DBaseline-2 weeks
b N 5 5 (study group)
group and the baseline values of the patients with chronic
allograft rejection could be demonstrated in the follow-
ing parameters: serum creatinine, creatinine clearance,
TGF-b1, and ET-1. No differences were observed in
blood pressure, ACE genotype distribution, and Ang II.
DISCUSSION
This study demonstrates, for the first time to our
knowledge in transplant patients with chronic allograft
nephropathy, that serum levels of TGF-b1 were signifi-
cantly higher than recipients with normal renal function
and that losartan could significantly decrease the plasma
Fig. 1. Follow-up of angiotensin II (Ang II; h) and transforming levels of TGF-b1. The decrease in TGF-b1 was greater
growth factor-b1 (TGF-b1; ,) during the treatment with losartan.
than 50% with respect to the basal levels, and at theResults are expressed as mean 6 sem.
end of the study, there was no significant difference with
respect to a control group of transplanted patients without
chronic allograft nephropathy. The reduction of TGF-b1
with a 95% CI (range 20.020, 20.004). The lnAng II was observed in all patients and was progressive through-
line slope was 0.030 with a 95% CI (0.053, 20.007). The out the study period. These results confirmed recent data
ET-1 and lnNOx results in the slope showed a variable from experimental animals and in vitro studies in which,
trend. The mean ET-1 line slope was 20.010 with a 95% using various models, ACE inhibitors and Ang II recep-
CI (0.002, 20.022), and the lnNOx line slope was 0.004 6 tor antagonists decreased the synthesis and secretion of
0.008. TGF-b1 time and Ang II time showed a significant renal TGF-b1 and prevented the development of intersti-
correlation in a profile analysis of the response features tial fibrosis and subsequently chronic nephropathy [10].
(P 5 0.02 and P 5 0.01, respectively). This protective effect has only been observed in ACE
A significant correlation was observed between TGF-b1 inhibitors and Ang II receptor antagonists, but not in
(basal, 8 weeks) and Ang II (basal, 2 weeks, P , 0.05). other antihypertensive drugs. The reduction in TGF-b1
No other statistical relationships could be demonstrated observed in this study is fairly consistent with the data
between TGF-b1 and ET-1 and NOx at different study from experimental animals (approximately 50%), al-
times in a bivariate correlation analysis. though in most of these studies, TGF-b1 levels remained
The analysis of ACE genotype has demonstrated that somewhat high. In the same way, Cottone et al demon-
10 patients were I/D genotype, three D/D, and one I/I. strated recently that losartan reduces circulating levels
No correlations were observed between ACE genotypes of both ET-1 and some growth factors, including basic
and TGF-b1, Ang II, ET-1, or NOx blood levels. fibroblast and platelet-derived growth factors [22].
The results of the control group are also summarized The mechanism by which losartan decreased serum
levels of TGF-b1 is through Ang II blockade. Ang IIin Table 1. Significant differences between the control
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stimulates the production and activation of TGF-b1 in needs to be clinically evaluated. Finally, Ang II receptor
the kidney via the angiotensin II type-1 (AT1) receptor, antagonists could have a therapeutic role in the treat-
and the activation of intrarenal RAS and the overexpres- ment or prevention of other chronic diseases with in-
sion of renal TGF-b1 via Ang II and cyclosporine A is creased fibrogenesis through TGF-b1, such as liver cir-
well known in chronic allograft nephropathy. In this rhosis, systemic sclerosis, cardiac hypertrophy, and
study, we demonstrated a significant correlation between asthma [28–31].
the increase in Ang II at two weeks and the decrease in
TGF-b1 at the end of the study period, suggesting that ACKNOWLEDGMENTS
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